Intra-Cellular Therapies, Inc. (ITCI)
131.87
0.00 (0.00%)
Inactive · Last trade price on Apr 1, 2025
Intra-Cellular Therapies Revenue
In the year 2024, Intra-Cellular Therapies had annual revenue of $680.85M with 46.62% growth. Intra-Cellular Therapies had revenue of $199.22M in the quarter ending December 31, 2024, with 50.81% growth.
Revenue (ttm)
$680.85M
Revenue Growth
+46.62%
P/S Ratio
19.97
Revenue / Employee
$791,688
Employees
860
Market Cap
14.02B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 680.85M | 216.48M | 46.62% |
Dec 31, 2023 | 464.37M | 214.06M | 85.51% |
Dec 31, 2022 | 250.31M | 166.51M | 198.69% |
Dec 31, 2021 | 83.80M | 60.99M | 267.35% |
Dec 31, 2020 | 22.81M | 22.75M | 37,537.14% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionITCI News
- 5 months ago - Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 8 months ago - INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI - Business Wire
- 8 months ago - Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewsWire
- 9 months ago - Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last? - CNBC
- 9 months ago - Top 4 Health Care Stocks You May Want To Dump In Q1 - Benzinga
- 9 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders - PRNewsWire
- 9 months ago - Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal - WSJ
- 9 months ago - Drugmakers rush to sign deals on first day of industry conference - Reuters